Selbex

ApprovedSmall molecule

Eisai

Selbex is one of 11 small molecule programs targeting Chronic Gastritis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic GastritisActive, not recruiting

Chronic GastritisApproved

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Chronic Gastritis

#DrugCompanyPhaseTrials

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 2

Mucosta

Otsuka

Phase 3

2 3

DWP14012

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 4

Reference

RRespirent Pharmaceuticals Co Ltd.

Phase 3

1 5

Test

RRespirent Pharmaceuticals Co Ltd.

Phase 3

1 6

Selbex

Eisai

Approved

1 7

DW1903-R1

Daewon Pharmaceutical Co., Ltd.

Phase 3

1 8

HIP2101

Hanmi Pharmaceutical Company Limited

Phase 3

1 9

DW1903

Daewon Pharmaceutical Co., Ltd.

Phase 3

1 10

RLD2101

Hanmi Pharmaceutical Company Limited

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Gastritis1 trial

Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer

Completed· Eisai logo

Eisai·Phase 4·NCT01190657·1,184 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Selbex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Selbex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Selbex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eisai

Selbex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Gastritis1 trial

References

Drug Info

Quick Facts

Related News